头对头优于司美格鲁肽,“减肥药双雄”正面交锋

国际金融报
09 Dec 2024

从药物研发到适应证拓展再到产能加码,GLP-1可谓是今年最“卷”的一类药物,也早早地就被市场寄予成为下一款“药王”的厚望。而随着礼来替尔泊肽最新研究成果的发布,“药王”之争愈发充满悬念。  近日,同诺和诺德并称“减肥药双雄”的礼来发布替尔泊肽最新研究成果。头对头研究显示,礼来替尔泊肽减重效果优于司美格鲁肽,后者为诺和诺德生产的GLP-1类减肥药。  今年年初以来,有关司美格鲁肽预定全球新“药王”的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10